GlaxoSmithKline plc (LON:GSK) had its target price upped by analysts at J P Morgan Chase & Co from GBX 1,670 ($21.13) to GBX 1,750 ($22.14) in a research report issued to clients and investors on Friday, May 12th. The brokerage presently has a “neutral” rating on the stock. J P Morgan Chase & Co’s price objective indicates a potential upside of 3.86% from the company’s current price.
Several other brokerages have also recently weighed in on GSK. Berenberg Bank upped their price target on GlaxoSmithKline plc from GBX 1,850 ($23.40) to GBX 1,890 ($23.91) and gave the company a “hold” rating in a research report on Friday, March 17th. HSBC Holdings plc reiterated a “buy” rating and set a GBX 1,970 ($24.92) price target on shares of GlaxoSmithKline plc in a research report on Wednesday, March 15th. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research report on Tuesday, March 7th. BNP Paribas restated an “underperform” rating and issued a GBX 1,520 ($19.23) price objective on shares of GlaxoSmithKline plc in a research report on Wednesday, March 22nd. Finally, Deutsche Bank AG restated a “hold” rating and issued a GBX 1,720 ($21.76) price objective on shares of GlaxoSmithKline plc in a research report on Friday, March 31st. Four analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of GBX 1,745.17 ($22.08).
GlaxoSmithKline plc (GSK) traded up 0.06% during trading on Friday, reaching GBX 1685.00. 19,969,256 shares of the company’s stock traded hands. The stock’s market cap is GBX 82.33 billion. The company’s 50 day moving average is GBX 1,647.07 and its 200-day moving average is GBX 1,604.10. GlaxoSmithKline plc has a 52-week low of GBX 1,363.00 and a 52-week high of GBX 1,745.56.
The business also recently disclosed a dividend, which will be paid on Thursday, July 13th. Stockholders of record on Thursday, May 11th will be paid a dividend of GBX 19 ($0.24) per share. This represents a dividend yield of 1.21%. The ex-dividend date is Thursday, May 11th.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/06/16/jpmorgan-chase-co-boosts-glaxosmithkline-plc-gsk-price-target-to-gbx-1750-updated-updated-updated.html.
In other GlaxoSmithKline plc news, insider Dominic Redfern purchased 230 shares of the company’s stock in a transaction that occurred on Thursday, April 13th. The stock was bought at an average price of GBX 1,639 ($20.73) per share, with a total value of £3,769.70 ($4,768.75). Also, insider Vivienne Cox purchased 335 shares of the company’s stock in a transaction that occurred on Wednesday, April 26th. The stock was acquired at an average cost of GBX 1,583 ($20.03) per share, with a total value of £5,303.05 ($6,708.48). In the last three months, insiders have bought 662 shares of company stock valued at $1,067,188.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.